73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Researchers find breast cancer protein that could predict chemotherapy sensitivity

Researchers find breast cancer protein that could predict chemotherapy sensitivity

by Hunter Medical Research InstituteThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: NCI Center for

Researchers find breast cancer protein that could predict chemotherapy sensitivity

by Hunter Medical Research InstituteThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: NCI Center for
Blood-based biomarker may redefine future treatment for advanced melanoma

Blood-based biomarker may redefine future treatment for advanced melanoma

byElsevierCirculating tumor DNA (ctDNA) correlates with radiology disease assessment and patient outcome. For patient A, biomarkers in their blood decreased over time and the radiology showed th

Blood-based biomarker may redefine future treatment for advanced melanoma

byElsevierCirculating tumor DNA (ctDNA) correlates with radiology disease assessment and patient outcome. For patient A, biomarkers in their blood decreased over time and the radiology showed th
Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

by Elana GotkineFor patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative co

Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

by Elana GotkineFor patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative co
New drug combinations could improve therapies for breast cancer, other aggressive cancers

New drug combinations could improve therapies for breast cancer, other aggressive cancers

by Angela Yeager,Oregon Health & Science UniversityQuantification of CD8+T cells by multispectral flow cytometry in an ex vivo co-culture assay. Credit:Cell Reports Medicine&nbsp

New drug combinations could improve therapies for breast cancer, other aggressive cancers

by Angela Yeager,Oregon Health & Science UniversityQuantification of CD8+T cells by multispectral flow cytometry in an ex vivo co-culture assay. Credit:Cell Reports Medicine&nbsp
Patients with cancer, suppressed immune system at high risk for severe COVID if treated with systemic drug therapies

Patients with cancer, suppressed immune system at high risk for severe COVID if treated with systemic drug therapies

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainPatients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than t

Patients with cancer, suppressed immune system at high risk for severe COVID if treated with systemic drug therapies

byDana-Farber Cancer InstituteCredit: Unsplash/CC0 Public DomainPatients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than t
Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which
Preclinical study finds novel bone cancer therapy has 99% success rate

Preclinical study finds novel bone cancer therapy has 99% success rate

byAston UniversityProfessor Richard Martin. Credit: Aston UniversityBioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined

Preclinical study finds novel bone cancer therapy has 99% success rate

byAston UniversityProfessor Richard Martin. Credit: Aston UniversityBioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined
Boosting immunotherapy in non-responsive cancer cells

Boosting immunotherapy in non-responsive cancer cells

by Surabhi Chandra,Indian Institute of ScienceAvik Chattopadhyay working in the lab. Credit: Nikita RamtekeCancer immunotherapy primes a patient's immune system to better find and destroy ca

Boosting immunotherapy in non-responsive cancer cells

by Surabhi Chandra,Indian Institute of ScienceAvik Chattopadhyay working in the lab. Credit: Nikita RamtekeCancer immunotherapy primes a patient's immune system to better find and destroy ca
Method that uses combination of immune cells could provide clearer prognoses

Method that uses combination of immune cells could provide clearer prognoses

by Elin Bäckström,Swedish Research CouncilPrognostic value of CD8+T cells and CD68+CD163+macrophages revealed by comprehensive characterization of immune cell subsets in 286 therapy-

Method that uses combination of immune cells could provide clearer prognoses

by Elin Bäckström,Swedish Research CouncilPrognostic value of CD8+T cells and CD68+CD163+macrophages revealed by comprehensive characterization of immune cell subsets in 286 therapy-
Gene loss enhances metastasis and cancer progression

Gene loss enhances metastasis and cancer progression

by Melissa Rohman,Northwestern UniversityAn in vivo genome-wide CRISPR-Cas9 KO screen identifying CTC-promoting genetic factors. (A) Experimental design of the genome-wide CRISPR-Cas9 KO screen

Gene loss enhances metastasis and cancer progression

by Melissa Rohman,Northwestern UniversityAn in vivo genome-wide CRISPR-Cas9 KO screen identifying CTC-promoting genetic factors. (A) Experimental design of the genome-wide CRISPR-Cas9 KO screen
Unveiling the non-canonical functions of EZH2 in prostate cancer

Unveiling the non-canonical functions of EZH2 in prostate cancer

by Impact Journals LLCProstate cancer cells. Credit: NIH Image GalleryA new editorial paper was published inOncotargettitled "Unveiling the non-canonical functions of EZH2 in prostate

Unveiling the non-canonical functions of EZH2 in prostate cancer

by Impact Journals LLCProstate cancer cells. Credit: NIH Image GalleryA new editorial paper was published inOncotargettitled "Unveiling the non-canonical functions of EZH2 in prostate
Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len